Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among […]
Royal Bank of Canada reaffirmed their sector perform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $54.00 target price on the biotechnology company’s stock. Several other analysts also recently weighed in on ENTA. Oppenheimer set a […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) – Equities researchers at Oppenheimer raised their FY2023 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a note issued to investors on Sunday, July 31st. Oppenheimer analyst J. Olson now anticipates that the biotechnology company will earn $2.04 per share for the year, up from their previous […]